Yuan Yi, Liu Tongpeng, Yao Yu, Ma Qingyue, Sun Lijiang, Zhang Guiming
Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Department of Ophthalmology, The Affiliated Hospital of Qingdao University, Qingdao, China.
BMC Urol. 2025 May 21;25(1):132. doi: 10.1186/s12894-025-01812-9.
This study employed bibliometric analysis to explore global research on metabolic syndrome (MetS) and bladder cancer (BC), focusing on characteristics and research trends. Additionally, a meta-analysis was conducted to comprehensively evaluate the association between MetS and its components with the risk of BC.
We conducted a comprehensive search of publications from 2002 to 2022 in the Web of Science Core Collection (WoSCC). Visualization analysis was performed using the Open Scientometrics Data Analysis and Visualization Platform, VOSviewer software and the R package "bibliometrix". For the meta-analysis, data from PubMed, Embase and the Cochrane Library up to March 22, 2022, were utilized. Literature from PubMed, Embase, Cochrane and Web of Science up to March 25, 2022, were retrieved, and data extraction was independently performed by two authors. A random-effects model was used to calculate pooled odds ratios (ORs) and 95% confidence intervals (95% CIs). Meta-analysis was conducted using RevMan 5.4 software.
In the bibliometric analysis, 147 papers were included, and information on countries, institutions, authors, journals and keywords from Web of Science was analyzed and visualized. For the meta-analysis, 11 studies involving 665,164 patients were included. The pooled analysis of six case-control studies showed that patients with MetS had a higher risk of BC compared to the non-MetS control group (OR = 1.62, 95% CI: 1.08-2.43, P < 0.01). Analysis of MetS components revealed that diabetes (OR = 0.44, 95% CI: 0.32-0.61, P < 0.01), low high-density lipoprotein (HDL) (OR = 0.29, 95% CI: 0.19-0.44, P < 0.01) and high triglycerides (OR = 0.59, 95% CI: 0.39-0.88, P < 0.01) were associated with an increased risk of BC. In contrast, hypertension (OR = 0.84, 95% CI: 0.62-1.12, P > 0.05) and obesity (OR = 0.8, 95% CI: 0.44-1.45, P > 0.05) showed no significant association with BC risk.
This study provided valuable insights into the association between MetS and BC risk by identifying past research trends and hotspots. MetS and its components, such as diabetes, low HDL and high triglycerides, were associated with an increased risk of BC.
本研究采用文献计量分析方法，探讨全球范围内关于代谢综合征（MetS）和膀胱癌（BC）的研究，重点关注其特征和研究趋势。此外，还进行了一项荟萃分析，以全面评估MetS及其各组分与BC风险之间的关联。
我们对2002年至2022年Web of Science核心合集（WoSCC）中的出版物进行了全面检索。使用开放科学计量数据分析与可视化平台、VOSviewer软件和R包“bibliometrix”进行可视化分析。对于荟萃分析，利用截至2022年3月22日来自PubMed、Embase和Cochrane图书馆的数据。检索了截至2022年3月25日来自PubMed、Embase、Cochrane和Web of Science的文献，并由两名作者独立进行数据提取。采用随机效应模型计算合并比值比（OR）和95%置信区间（95%CI）。使用RevMan 5.4软件进行荟萃分析。
在文献计量分析中，纳入了147篇论文，并对来自Web of Science的国家、机构、作者、期刊和关键词信息进行了分析和可视化。对于荟萃分析，纳入了11项涉及665164名患者的研究。六项病例对照研究的合并分析表明，与非MetS对照组相比，MetS患者患BC的风险更高（OR = 1.62，95%CI：1.08 - 2.43，P < 0.01）。对MetS各组分的分析显示，糖尿病（OR = 0.44，95%CI：0.32 - 0.61，P < 0.01）、低高密度脂蛋白（HDL）（OR = 0.29，95%CI：0.19 - 0.44，P < 0.01）和高甘油三酯（OR = 0.59，95%CI：0.39 - 0.88，P < 0.01）与BC风险增加相关。相比之下，高血压（OR = 0.84，95%CI：0.62 - 1.12，P > 0.05）和肥胖（OR = 0.8，95%CI：0.44 - 1.45，P > 0.05）与BC风险无显著关联。
本研究通过识别过去的研究趋势和热点，为MetS与BC风险之间的关联提供了有价值的见解。MetS及其组分，如糖尿病、低HDL和高甘油三酯，与BC风险增加相关。
